PP01.59: ABBIL1TY NSCLC-06: A Global, Randomized, Open-Label, Phase 3 Trial of Acasunlimab in Combination with Pembrolizumab vs Docetaxel in Checkpoint Inhibitor–Experienced Patients with PD-L1+ Metastatic Non-Small Cell Lung Cancer

Journal of Thoracic Oncology 2026

View at publisher
Authors: Luis Paz-Ares, Benjamin Besse, Michael Thomas, Joachim Aerts, James Chih-Hsin Yang, Joel Michalski, James Thomas D'Olimpio, Kazuo Kasahara, Yasuhito Fujisaka, Kammei Rai, Hye Ryun Kim, Keon Uk Park
+6 more Myung-Ju Ahn, Alexandros Georgiou, Thomas Mark, Claudio Missarelli Poggi, Mariana Sacchi, Charu Aggarwal
DOI: 10.1016/j.jtho.2026.103802
Cited by: 1

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Research Studies

Publication details

Journal / source
Journal of Thoracic Oncology
Publisher
Elsevier BV
Volume
21
Issue
5
Pages
103802–103802
Publication date
1 May 2026
Language
EN